Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estradiol + leuprolide acetate is a combination therapy consisting of estradiol, a natural estrogen hormone, and leuprolide acetate, a synthetic gonadotropin-releasing hormone (GnRH) agonist. This combination is sometimes used as an "add-back" regimen during GnRH agonist therapy for conditions such as endometriosis to mitigate hypoestrogenic side effects like bone mineral density loss and vasomotor symptoms. Leuprolide acetate works by initially stimulating and then downregulating pituitary GnRH receptors, leading to decreased production of gonadal steroids (estrogen in women), which helps suppress endometriosis-related pain. Estradiol is added after several months of GnRH agonist therapy to reduce menopausal-like side effects but may risk recurrence or worsening of endometriosis symptoms[3][10]. The use of this specific combination is less common than the use of leuprolide with progestins (such as norethindrone), due to concerns about pain recurrence with estrogen add-back[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + leuprolide acetate.